Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06393517 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT06393517 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 23 participants.
The verdict
NCT06393517, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to compare three finished products of PF-06954522 in terms of the uptake into the blood stream. This study is seeking participants who are: \- Healthy male or female participants aged 18 years or older. All participants in this study will receive PF-06954522 once by mouth. The participants may receive different tablets by mouth for PF-06954522. The study will compare experiences of people receiving three different products of PF-06954522. This will help understand how much PF-06954522 is taken up into the blood for each product given. Participants will take part into the study for about 77 days. During this time participants will have to stay onsite for 21 days. There will be one follow up (by telephone) study visit.
Interventions
- DRUG PF-06954522 IR (Formulation 1)
- DRUG PF-06954522 MR (Formulation 2)
- DRUG PF-06954522 MR (Formulation 3)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2024-04-30 |
| Est. Completion | 2024-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06393517
The ClinicalTrials.gov registry entry for NCT06393517 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PF-06954522 IR (Formulation 1) is the first listed.
NCT06393517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06393517 about?
NCT06393517 is a clinical study titled "A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults". The purpose of this study is to compare three finished products of PF-06954522 in terms of the uptake into the blood stream. This study is seeking participants who are: \- Healthy male or female participants aged 18 years or older. All participants in this study will receive PF-06954522 once by m...
What is the current status of trial NCT06393517?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2024-04-30. Estimated completion is 2024-09-01.
What interventions are being tested in trial NCT06393517?
The interventions under investigation include: PF-06954522 IR (Formulation 1) (DRUG), PF-06954522 MR (Formulation 2) (DRUG), PF-06954522 MR (Formulation 3) (DRUG).
Who is sponsoring clinical trial NCT06393517?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.